The global High Potency Active Pharmaceutical Ingredient (HPAPI) market garnered revenue around USD 17.52 Billion in 2019 and projected to reach USD 36.85 Billion in 2027, with at a compound annual growth rate (CAGR) 8.6% throughout the estimate period from 2020 to 2027.
High-potency active pharmaceutical ingredients (HPAPIs) are a niche but growing area for pharmaceutical manufacturers and contract manufacturing organizations (CMOs). Specialized considerations in facility design, equipment, operation, and process safety are needed to achieve the desired level of containment of the drug substance or finished-drug product. For drug-substance manufacturing, the HPAPI may be a small-molecule, biologic, or a hybrid of the two such as an antibody–drug conjugate, which links a cytotoxic small-molecule to a monoclonal antibody.
High potency active pharmaceutical ingredients (HPAPI) form a significant proportion of new drugs under development. Production of HPAPI presents various challenges due to its cytotoxic nature; thus, it requires heavy investment to ensure safe environment for employees. Contract manufacturing of HPAPI has been preferred over captive production due to high degree of competition and reduced profitability. Contract manufacturing is also preferred due to geographical advantage and cost-effectiveness.
North America dominate the global High Potency Active Pharmaceutical Ingredients (HPAPI) market in 2019 and the trend is anticipated to continue during the forecast period. High demand for biological HPAPI, technological development in the pharmaceutical industry, and large number of manufacturing facilities are major factors driving the market growth in these regions.
Asia Pacific is likely to be a highly lucrative region for the High Potency Active Pharmaceutical Ingredients (HPAPI) market and is expected to expand at a high CAGR during the forecast period due to rising focus on contract manufacturing and contract research organizations. Low labor cost, well-equipped manufacturing plants, and favorable foreign exchange policies in countries such as China have created lucrative opportunities for outsourcing businesses. Additionally, pharmaceutical manufacturers are currently focusing on countries in Latin America for contract manufacturing.
This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.
The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the High Potency Active Pharmaceutical Ingredient (HPAPI) market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the High Potency Active Pharmaceutical Ingredient (HPAPI) market growth.
The global High Potency Active Pharmaceutical Ingredient (HPAPI) market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.
Major manufacturers analysed under this study comprises:
The global High Potency Active Pharmaceutical Ingredients (HPAPI) market include Alkermes plc, Cambrex Corporation, Dr. Reddy's Laboratories, Lonza Group, Novasep, Novartis AG, Pfizer, Sigma-Aldrich Co. LLC., WuXi AppTec, Bristol-Myers Squibb, F. Hoffmann-La Roche, Teva Pharmaceutical Industries, Eli Lilly and Company, Abbvie.
This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:
- Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market, by API Type
- Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market, by Manufacture Type
- Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market, by Drug Type
- Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market, by Therapeutic Application
- Oncology Drugs
- Anti-diabetic Drugs
- Cardiovascular Drugs
- CNS Drugs
- Musculoskeletal Drugs
- Other Drugs
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
- North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Rest of EU
- Asia Pacific
- China
- India
- Japan
- Southeast Asia
- Rest of APAC
- Central & South America
- Brazil
- Argentina
- Rest of Central & South America
- Middle East and Africa
- UAE
- Saudi Arabia
- Rest of MEA
Request Customization
Get a Sample
Get a Sample
Request Customization